Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Availability of endothelial von Willebrand factor and platelet function in diabetic patients infused with a vasopressin analogue

  • 59 Accesses

  • 10 Citations

Summary

Acute release of von Willebrand factor and its immunologically detected correspondent, factor VIII-related antigen, from the endothelial cells into the circulation was induced by an infusion of 1-deamino-8-D-arginine vasopressin in eight normal subjects and eight insulin-dependent diabetic patients. The patients had higher basal levels of von Willebrand factor (140±13%) and VIII-related antigen (112±18%) than the normal subjects (95±5% and 70±8%, respectively). 1-deamino-8-D-arginine vasopressin induced a two fold rise of these levels in both groups, von Willebrand factor/ VIII-related antigen remaining higher in the diabetic patients throughout the experiment. In the normal subjects, platelet retention in glass bead columns increased soon after the infusion but returned to basal values after 2 h. In the patients, it remained high at the end of the infusion. No changes in platelet aggregation occurred. These results suggest that increased plasma von Willebrand factor/VIII-related antigen in diabetic patients is accompanied by an increased endothelial content of this factor.

References

  1. 1.

    Bloom AL (1979) The biosynthesis of factor VIII. Clin Haematol 8:53–77

  2. 2.

    Bensoussan D, Levy-Toledano S, Passa P, Caen J, Canivet J (1975) Platelet hyperaggregation and increased plasma levels of von Willebrand factor in diabetics with retinopathy. Diabetologia 11: 307–312

  3. 3.

    Coller BS, Frank RN, Milton RC, Gralnick HR (1978) Plasma cofactors of platelet function: correlation with diabetic retinopathy and haemoglobins A1a-c. Studies in diabetic patients and normal persons. Ann Intern Med 88: 311–316

  4. 4.

    Gensini GF, Abbate R, Favilla S, Neri Serneri GG (1979) Changes of platelet function and blood clotting in diabetic retinopathy. Thromb Haemost 42: 983–993

  5. 5.

    Porta M, Townsend C, Clover GM, Nanson M, Alderson AR, McCraw A, Kohner EM (1981) Evidence for functional endothelial cell damage in early diabetic retinopathy. Diabetologia 20: 597–601

  6. 6.

    Webster J, Porta M, Hensby CN, Kohner EM, Lewis PJ (1981) Plasma levels of 6-oxo-PGF: the hydrolysis product of prostacyclin may be reduced in diabetes. In: Lewis PJ and O'Grady J (eds) Clinical pharmacology of prostacyclin. Raven Press, New York, pp 113–115

  7. 7.

    Aimèr L-O, Pandolfi M (1976) Fibrinolysis and diabetic retinopathy. Diabetes 25: 807–810

  8. 8.

    Mayne EE, Bridges JM, Weaver JA (1970) Platelet adhesiveness, plasma fibrinogen and factor VIII levels in diabetes mellitus. Diabetologia 6: 436–440

  9. 9.

    Heath H, Bridgen WD, Canever JV, Pollock J, Hunter PR, Kelsey J, Bloom A (1971) Platelet adhesiveness and aggregation in relation to diabetic retinopathy. Diabetologia 7: 308–315

  10. 10.

    Draminski-Petersen H, Gormsen J (1978) Platelet aggregation in diabetes mellitus. Acta Med Scand 203:125–130

  11. 11.

    Corbella E, Miragliotta G, Masperi R, Villa S, Bini A, de Gaetano G, Chiumello G (1979) Platelet aggregation and antithrombin III in diabetic children. Haemostasis 8: 30–37

  12. 12.

    Porta M, Hilgard P, Kohner EM (1980) Platelet shape change abnormalities in diabetic retinopathy. Diabetologia 18: 217–221

  13. 13.

    Baumgartner HR (1972) Platelet interactions with vascular structures. Thromb Diath Haemorrh (Suppl) 51: 161–176

  14. 14.

    Salzman EW (1963) Measurement of platelet adhesiveness. A simple in vitro technique demonstrating an abnormality in von Willebrand's disease. J Lab Clin Invest 62: 724–735

  15. 15.

    Sarji KE, Schraibman HB, Chambers AL, Nair RMG, Colwell JA (1976) Quantitative studies of von Willebrand factor (vWF) in normal and diabetic subjects: role of vWF in second-phase platelet aggregation. In: Grayson J, Zingg E (eds) Microcirculation, Vol 2. Plenum Press, New York, pp 296–297

  16. 16.

    Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) 1-deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. LancetI: 869–872

  17. 17.

    Desirable body weights of adults (1970) In: Diem K, Lentner C (eds) Scientific tables. Geigy, Basel, p 712

  18. 18.

    Porta M, Maneschi F, White MC, Kohner EM (1981) Twenty-four hour variations of von Willebrand factor and factor VIII-related antigen in diabetic retinopathy. Metabolism 30: 695–699

  19. 19.

    Laurell CB (1972) Electroimmunoassay. Scand J Clin Lab Invest 29: 21–37

  20. 20.

    Nilsson IM, Holmberg M, Aberg M, Vilhardt H (1980) The release of plasminogen activator and factor VIII after injection of DDAVP in healthy volunteers and in patients with von Willebrand's disease. Scand J Haematol 24: 351–359

  21. 21.

    Menon C, Berry EW, Ockelford P (1978) Beneficial effect of DDAVP on bleeding-time in von Willebrand's disease. Lancet II: 743–744

  22. 22.

    Nilsson IM, Walter H, Mikaelsson M, Vilhadt H (1979) Factor VIII concentrate prepared from DDAVP stimulated blood donor plasma. Scand J Haematol 22: 42–46

  23. 23.

    Odegaard AE, Skaihegg BA, Hellem AJ (1964) Increased activity of ‘anti-Willebrand factor’ in diabetic plasma. Thromb Diath Haemorrh 11: 27–37

  24. 24.

    Cash JD, Gader AM, Mulder JM, Cort JH (1978) Structure-activity relations of the fibrinolytic response to vasopressins in man. Clin Sci Mol Med 54: 403–409

  25. 25.

    Porta M, Cagliero E, Kohner EM (1982) Is the pro-adhesive activity of plasma von Willebrand factor counteracted by a physiological inhibitor of platelet adhesiveness? Clin Sci 62: 239–242

  26. 26.

    Preston FE, Whipps S, Jackson CA, French AJ, Wyld PJ, Stod-dard CJ (1981) Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin. N Engl J Med 304: 76–79

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Porta, M. Availability of endothelial von Willebrand factor and platelet function in diabetic patients infused with a vasopressin analogue. Diabetologia 23, 452–455 (1982). https://doi.org/10.1007/BF00260961

Download citation

Key words

  • Plasma coagulation factors
  • von Willebrand factor
  • platelet adhesiveness
  • platelet aggregation
  • argipressin
  • diabetes mellitus
  • diabetic microangiopathy